




Searching News Database: cyclosporine
HSMN NewsFeed - 18 Aug 2023
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy
HSMN NewsFeed - 20 Apr 2021
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
HSMN NewsFeed - 16 Mar 2020
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
HSMN NewsFeed - 30 May 2018
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
HSMN NewsFeed - 19 Oct 2017
Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis(R)
Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis(R)
HSMN NewsFeed - 17 Feb 2011
Inspire Announces Corporate Restructuring and Strategic Focus on Eye Care Business
Inspire Announces Corporate Restructuring and Strategic Focus on Eye Care Business
HSMN NewsFeed - 3 Jan 2011
Inspire Announces Results of Second Phase 3 Trial with Denufosol for Cystic Fibrosis
Inspire Announces Results of Second Phase 3 Trial with Denufosol for Cystic Fibrosis
HSMN NewsFeed - 1 Sep 2010
Inspire Names Robert Savel as Senior Vice President and Chief Technical Officer
Inspire Names Robert Savel as Senior Vice President and Chief Technical Officer
HSMN NewsFeed - 13 Apr 2010
Inspire Appoints Andrew Koven as Executive Vice President and Chief Administrative and Legal Officer
Inspire Appoints Andrew Koven as Executive Vice President and Chief Administrative and Legal Officer
HSMN NewsFeed - 3 Mar 2010
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
HSMN NewsFeed - 23 Dec 2009
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
HSMN NewsFeed - 8 Jul 2009
GTC Biotherapeutics in-Licenses Recombinant Human Alpha-Fetoprotein from Merrimack Pharmaceuticals
GTC Biotherapeutics in-Licenses Recombinant Human Alpha-Fetoprotein from Merrimack Pharmaceuticals
HSMN NewsFeed - 19 Feb 2009
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
HSMN NewsFeed - 25 Nov 2008
Watson Enters Into Agreement to Acquire Products Related to Teva's Proposed Acquisition of Barr
Watson Enters Into Agreement to Acquire Products Related to Teva's Proposed Acquisition of Barr
HSMN NewsFeed - 6 Nov 2008
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
HSMN NewsFeed - 4 Nov 2008
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
HSMN NewsFeed - 18 Sep 2008
Enbrel(R) Shown to Deliver Long-Lasting Improvements in Psoriasis Patients' Quality of Life
Enbrel(R) Shown to Deliver Long-Lasting Improvements in Psoriasis Patients' Quality of Life
HSMN NewsFeed - 14 Aug 2008
Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
HSMN NewsFeed - 24 Jun 2008
NICE Recommends Abbott's Adalimumab (HUMIRA(R)) for the Treatment of Chronic Plaque Psoriasis
NICE Recommends Abbott's Adalimumab (HUMIRA(R)) for the Treatment of Chronic Plaque Psoriasis
HSMN NewsFeed - 6 Jun 2008
Inspire Announces Achievement of Primary Endpoint in Phase 3 Trial with Denufosol for Cystic Fibrosis
Inspire Announces Achievement of Primary Endpoint in Phase 3 Trial with Denufosol for Cystic Fibrosis
HSMN NewsFeed - 16 Apr 2008
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
HSMN NewsFeed - 30 Jan 2008
Lux Granted Fast Track Designation for LX201 for Corneal Transplant Rejection
Lux Granted Fast Track Designation for LX201 for Corneal Transplant Rejection
HSMN NewsFeed - 25 Jan 2008
Merck and Schering-Plough Respond To Issues Raised About ENHANCE Clinical Trial
Merck and Schering-Plough Respond To Issues Raised About ENHANCE Clinical Trial
HSMN NewsFeed - 14 Jan 2008
Merck/Schering-Plough Pharmaceuticals Provides Results of the ENHANCE Trial
Merck/Schering-Plough Pharmaceuticals Provides Results of the ENHANCE Trial
HSMN NewsFeed - 14 Jan 2008
Encysive Pharmaceuticals Launches THELIN (sitaxentan sodium) in Belgium and Luxembourg
Encysive Pharmaceuticals Launches THELIN (sitaxentan sodium) in Belgium and Luxembourg
HSMN NewsFeed - 20 Dec 2007
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
HSMN NewsFeed - 8 Nov 2007
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
HSMN NewsFeed - 6 Nov 2007
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
HSMN NewsFeed - 25 Oct 2007
Sirion Therapeutics Announces Positive Phase III Results for Difluprednate
Sirion Therapeutics Announces Positive Phase III Results for Difluprednate
HSMN NewsFeed - 21 Sep 2007
Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
HSMN NewsFeed - 13 Sep 2007
Encysive Pharmaceuticals Announces Launch of THELIN (sitaxentan sodium) in Spain
Encysive Pharmaceuticals Announces Launch of THELIN (sitaxentan sodium) in Spain
HSMN NewsFeed - 13 Aug 2007
Inspire Pharmaceuticals Launches AzaSite(TM) in the United States for Ocular Infections
Inspire Pharmaceuticals Launches AzaSite(TM) in the United States for Ocular Infections
HSMN NewsFeed - 7 Aug 2007
Lux Granted Fast Track Designation by FDA for LX211 for the Treatment of Uveitis
Lux Granted Fast Track Designation by FDA for LX211 for the Treatment of Uveitis
HSMN NewsFeed - 27 Jun 2007
Aspreva and Roche announce preliminary results for phase III study evaluating CellCept in lupus nephritis
Aspreva and Roche announce preliminary results for phase III study evaluating CellCept in lupus nephritis
HSMN NewsFeed - 7 Jun 2007
Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
HSMN NewsFeed - 7 Jun 2007
Inspire Adds Stephen D. Celestini as Senior Vice President and Chief Compliance Officer
Inspire Adds Stephen D. Celestini as Senior Vice President and Chief Compliance Officer
HSMN NewsFeed - 6 Jun 2007
Aspreva announces Fast-Track designation granted by the FDA for CellCept in lupus nephritis
Aspreva announces Fast-Track designation granted by the FDA for CellCept in lupus nephritis
HSMN NewsFeed - 1 Jun 2007
FDA Approves Norditropin(R)for Treatment of Short Stature Associated with a Rare Genetic Disorder
FDA Approves Norditropin(R)for Treatment of Short Stature Associated with a Rare Genetic Disorder
HSMN NewsFeed - 30 May 2007
Canadian Health Authority Approves THELIN (Sitaxsentan Sodium) for Pulmonary Arterial Hypertension
Canadian Health Authority Approves THELIN (Sitaxsentan Sodium) for Pulmonary Arterial Hypertension
HSMN NewsFeed - 7 May 2007
Early Results of the CellCept(R) Spare the Nephron Study Examine Kidney Function
Early Results of the CellCept(R) Spare the Nephron Study Examine Kidney Function
HSMN NewsFeed - 30 Apr 2007
Sebivo(R) (Telbivudine) Approved in European Union as a New Treatment for Chronic Hepatitis B Patients
Sebivo(R) (Telbivudine) Approved in European Union as a New Treatment for Chronic Hepatitis B Patients
HSMN NewsFeed - 18 Apr 2007
Schering-Plough Announces ZETIA Approved in Japan for Treatment of High Cholesterol
Schering-Plough Announces ZETIA Approved in Japan for Treatment of High Cholesterol
HSMN NewsFeed - 16 Apr 2007
Encysive Pharmaceuticals Announces Launch of THELIN (Sitaxentan Sodium) in the Netherlands
Encysive Pharmaceuticals Announces Launch of THELIN (Sitaxentan Sodium) in the Netherlands
HSMN NewsFeed - 2 Apr 2007
Encysive Pharmaceuticals Announces Launch of Thelin (Sitaxentan Sodium) in Republic of Ireland
Encysive Pharmaceuticals Announces Launch of Thelin (Sitaxentan Sodium) in Republic of Ireland
HSMN NewsFeed - 26 Mar 2007
Merck and Schering-Plough to Develop Another New Cholesterol Lowering Medicine
Merck and Schering-Plough to Develop Another New Cholesterol Lowering Medicine
HSMN NewsFeed - 2 Mar 2007
SEBIVO(R) (Telbivudine) Approved in China as New Treatment Option for Patients with Chronic Hepatitis B
SEBIVO(R) (Telbivudine) Approved in China as New Treatment Option for Patients with Chronic Hepatitis B
HSMN NewsFeed - 2 Feb 2007
FDA Approves New Dosing Recommendations for RAPAMUNE in High Immunologic Risk Renal Transplant Patients
FDA Approves New Dosing Recommendations for RAPAMUNE in High Immunologic Risk Renal Transplant Patients
HSMN NewsFeed - 15 Jan 2007
Lux Biosciences Receives Orphan Drug Designation from the FDA for Two Ophthalmic Products
Lux Biosciences Receives Orphan Drug Designation from the FDA for Two Ophthalmic Products
HSMN NewsFeed - 12 Jan 2007
Astellas Pharma US, Inc. Announces Availability of MYCAMINE(R) 100mg Vial
Astellas Pharma US, Inc. Announces Availability of MYCAMINE(R) 100mg Vial
HSMN NewsFeed - 26 Dec 2006
Astellas Pharma US, Inc. Submits Supplemental New Drug Application For Antifungal Product MYCAMINE(R)
Astellas Pharma US, Inc. Submits Supplemental New Drug Application For Antifungal Product MYCAMINE(R)
HSMN NewsFeed - 9 Nov 2006
Study in Today's New England Journal of Medicine Shows Benefits of Thymoglobulin Use
Study in Today's New England Journal of Medicine Shows Benefits of Thymoglobulin Use
HSMN NewsFeed - 26 Oct 2006
Aspreva Pharmaceuticals Announces Preliminary Results of Phase III Trial of CellCept for Myasthenia Gravis
Aspreva Pharmaceuticals Announces Preliminary Results of Phase III Trial of CellCept for Myasthenia Gravis
HSMN NewsFeed - 24 Jul 2006
Sirion Therapeutics Acquires U.S. License to Develop New Ophthalmic Compound
Sirion Therapeutics Acquires U.S. License to Develop New Ophthalmic Compound
HSMN NewsFeed - 19 Jul 2006
Dade Behring Launches Tacrolimus Test on Its Dimension(R), V-Twin(R), and Viva-E(TM) Systems
Dade Behring Launches Tacrolimus Test on Its Dimension(R), V-Twin(R), and Viva-E(TM) Systems
Additional items found! 105

Members Archive contains
105 additional stories matching:
cyclosporine
(Password required)
cyclosporine
(Password required)